Author Interviews, C. difficile, Gastrointestinal Disease, Imperial College, Infections, Transplantation / 30.04.2020
Fecal Microbiota Transplant For Multi-Drug-Resistant Organisms: Improved clinical Outcomes Beyond Intestinal Decolonization
MedicalResearch.com Interview with:
[caption id="attachment_54022" align="alignleft" width="149"]
Prof. Marchesi[/caption]
Prof. Julian Marchesi PhD
Professor of Digestive Health
Faculty of Medicine, Department of Metabolism, Digestion and Reproduction
[caption id="attachment_54021" align="alignleft" width="149"]
Prof. Mullish[/caption]
Dr. Benjamin Mullish PhD
Faculty of Medicine, Department of Metabolism, Digestion and Reproduction
NIHR Clinical Lecturer
Imperial College London
MedicalResearch.com: What is the background for this study?
Response: Many patients are colonized with bacteria that are resistant to nearly all the antibiotics that we currently have. This antibiotic resistance is a huge public health problem, not least because it may lead to the scenario where a bacterial species moves from the gut and into the bloodstream, causes an infection, and cannot be treated. Such scenarios particularly occur in patients who are particularly prone to getting multiple and frequent courses of antibiotics; this may include patients with particular kidney conditions (who may be vulnerable to recurrent urinary tract infections (UTIs)), and patients with blood cancers (such as leukaemia, who have weak immune systems and are therefore prone to infections).
Furthermore, in both sets of patients, to help treat their disease, they may be offered transplants, either a new kidney or new bone marrow. When this transplant happens, the clinician needs to ‘switch off’ their immune system to allow the transplant to work. When the immune system is dialled down, it can no longer stop any invading bacteria, increasing the chance of antibiotic resistance bacteria causing infections, which frequently leads to patient death.
Prof. Marchesi[/caption]
Prof. Julian Marchesi PhD
Professor of Digestive Health
Faculty of Medicine, Department of Metabolism, Digestion and Reproduction
[caption id="attachment_54021" align="alignleft" width="149"]
Prof. Mullish[/caption]
Dr. Benjamin Mullish PhD
Faculty of Medicine, Department of Metabolism, Digestion and Reproduction
NIHR Clinical Lecturer
Imperial College London
MedicalResearch.com: What is the background for this study?
Response: Many patients are colonized with bacteria that are resistant to nearly all the antibiotics that we currently have. This antibiotic resistance is a huge public health problem, not least because it may lead to the scenario where a bacterial species moves from the gut and into the bloodstream, causes an infection, and cannot be treated. Such scenarios particularly occur in patients who are particularly prone to getting multiple and frequent courses of antibiotics; this may include patients with particular kidney conditions (who may be vulnerable to recurrent urinary tract infections (UTIs)), and patients with blood cancers (such as leukaemia, who have weak immune systems and are therefore prone to infections).
Furthermore, in both sets of patients, to help treat their disease, they may be offered transplants, either a new kidney or new bone marrow. When this transplant happens, the clinician needs to ‘switch off’ their immune system to allow the transplant to work. When the immune system is dialled down, it can no longer stop any invading bacteria, increasing the chance of antibiotic resistance bacteria causing infections, which frequently leads to patient death.




Dr. Jeffrey Smith[/caption]
Jeffrey R. Smith, MD PhD
Department of Medicine, Division of Genetic Medicine
Vanderbilt-Ingram Cancer Center, and Vanderbilt Genetics Institute
Vanderbilt University Medical Center
Medical Research Service
Tennessee Valley Healthcare System, Veterans Administration
Nashville, TN
MedicalResearch.com: What is the background for this study?
Response: Roughly 20% of men with prostate cancer have a family history of the disease, and 5% meet criteria for hereditary prostate cancer. Although prostate cancer has the greatest heritability of all common cancers (twice that of breast cancer), extensive heterogeneity of its inherited causes has presented a considerable obstacle for traditional pedigree-based genetic investigative approaches. Inherited causes across, as well as within families are diverse.
This study introduced a new familial case-control study design that uses extent of family history as a proxy for genetic burden. It compared a large number of men with prostate cancer, each from a separate family with a strong history of the disease, to screened men with no personal or family history. The study comprehensively deconstructs how the 8q24 chromosomal region impacts risk of hereditary prostate cancer, introducing several new analytical approaches. The locus had been known to alter risk of prostate, breast, colon, ovarian, and numerous additional cancers.